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ABSTRACT
Introduction Uncontrolled haemorrhage is the leading 
cause of death on the battleield, and two-thirds of these 
deaths result from non-compressible haemorrhage. Blood 
salvage and autotransfusion represent an alternative to 
conventional blood transfusion techniques for austere 
environments, potentially providing blood to the casualty 
at point of injury. The aim of this paper is to describe the 
design, development and initial proof-of-concept testing 
of a portable blood salvage and autotransfusion tech-
nology to enhance survivability of personnel requiring 
major medical interventions in austere or military 
environments.
Method A manually operable, dual-headed pump was 
developed that removes blood from site of injury to a 
collection reservoir (upper pump) and back to casualty 
(lower pump). Theoretical low rate calculations deter-
mined pump coniguration and a three-dimensionally 
printed peristaltic pump was manufactured. Flow rates 
were tested with fresh bovine blood under labora-
tory conditions representative of the predicted clinical 
environment.
Results Mathematical modelling suggested low rates 
of 3.6 L/min and 0.57 L/min for upper and lower pumps. 
Using fresh bovine blood, low rates produced were 
2.67 L/min and 0.43 L/min. To mimic expected battleield 
conditions, upper suction pump low rate was calculated 
using a blood/air mixture.
Conclusion The authors believe that this technology can 
potentially enhance survivability for casualties in austere 
and deployed military settings through autotransfusion 
and cell concentration. It reduces negative effects of blood 
donation on the conventional donor pool, and potentially 
negates the logistical constraints associated with allo-
genic transfusions.
INTRODUCTION
Uncontrolled haemorrhage is the leading cause 
of death on the battlefield,1 in which two-thirds 
of these deaths are a result of non-compressible 
(truncal) haemorrhage.2 In Iraq and Afghanistan, 
uncontrolled blood loss was the cause of death in 
85% of the potentially survivable battlefield cases 
and in 80% of those who died in a military treat-
ment facility.3 Between 2001 and 2011 in these 
conflicts, 25% of the 4596 combat deaths were 
potentially survivable, and 90% of the deaths 
occurred before the injured personnel reached a 
medical facility. Of the 4090 mortally wounded 
troops, 1391 died instantly and 2699 died before 
reaching a treatment facility; only 506 reached a 
hospital before succumbing to injury. These data 
highlight an obvious need for improving field treat-
ment capability.4 
Over 25% of military casualties require aggres-
sive and urgent haemostatic resuscitation to increase 
survivability.5 Additionally, 30%40% of these 
casualties that need blood transfusions when they 
reach emergency departments also suffer from acute 
traumatic coagulopathy (ATC).68 This is associated 
with an 80% mortality rate9 10 and is related to the 
resuscitation regime. Variations of blood trans-
fusion techniques are possible, although very few 
blood restoration modalities are available to a field 
medic in austere conditions, due to blood provision 
and storage constraints. The urgent deployment of 
blood products (fresh frozen plasma and packed 
red blood cells) has been shown to attenuate ATC, 
although there are considerable logistical concerns 
and clinical risk with this type of intervention.11 As 
such, there is a need to develop innovative and less 
logistically intense mechanisms for treating casual-
ties that require blood at point of injury.
Recent damage control resuscitation proto-
cols have modified the ratios of blood elements 
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Key messages
 Ź Haemorrhage remains the most common 
cause of fatalities in military personnel under 
battleield conditions.
 Ź It is challenging to make adequate provision for 
blood replacement therapy using conventional 
means in the battleield.
 Ź Autotransfusion, a common blood replacement 
technique in civilian settings, is not currently 
suited to the austere or deployed military 
environment.
 Ź A novel autotransfusion system is described for 
use in austere settings, to follow the casualty 
journey from irst contact, through evacuation 
and into the hospital setting.
 Ź This device can be manually powered and is 
capable of handling up to 3 L/min of blood, 
returning it directly back to casualty.
 Ź The device promises to considerably reduce 
the mortality associated with major blood loss 
under battleield conditions.
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Figure 1 Design concept of the autotransfusion and cell concentration technology. The schematic of the blood salvage innovation (left), and as a 
lat-packed ield-deployable kit (right).
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administered to military casualties.12 These have signalled the 
necessary implementation of whole fresh warm blood (WFWB) 
administration in combat hospitals, where buddy transfu-
sions have exceeded 6000 units in recent combat operations.13 
Although WFWB transfusions in the battlefield are feasible, and 
have been shown to aid effectiveness of clotting and oxygen 
transport, there is still potential for catastrophic outcomes such 
as haemolytic reactions.14 15 Additional considerations include 
that donors are unable to provide more than a single unit, they 
require fluid therapy, they are limited to light duty for at least 
72 hours following donation and are restricted from flying 
duties for this time period.16 17 Military blood transfusions rely 
on donations from the general public and military personnel 
for treating massive blood loss in casualties. In 2013, 8000 
blood components from UK donors were shipped overseas to 
combat zones, which required safe and sterile transportation 
over thousands of miles to military hospitals. Donated blood has 
been shown to increase death rates, accentuate bleeding, and it 
carries risk of biological reactions.18 Transfusion reactions are 
difficult to recognise in severely or multiply injured casualties. 
Haemolytic reactions present acutely with fever, dyspnoea and 
renal failure and delayed reactions may occur.19 To avoid these 
deleterious consequences, our proposed innovation allows the 
patients own blood to be collected and recycled, a process 
known as autotransfusion.
Our group has previously developed an autotransfusion 
device for blood cell salvage in non-military clinical applica-
tions.20 HemoSep (Brightwake, Nottingham, UK) is a portable 
intraoperative blood salvage device that achieves effective blood 
recycling. It concentrates the residual blood during and after an 
operative procedure, returning all cell species including plate-
lets, red and white blood cells, and proteins and clotting resid-
uals back to the patient. This technology has been successfully 
and broadly used in a wide range of applications.21 It is capable 
of reducing blood loss in cardiac and other types of clean site 
procedures, including paediatric surgery. HemoSeps blood bag 
component uses a membrane-controlled superabsorber-driven 
plasma removal process which can preserve all cell species 
and remove contaminants prior to re-transfusion. The control 
membrane has a pore size that prevents migration of cellular 
species from the blood to the superabsorber, while allowing free 
passage of diluted plasma into the superabsorbent polymer. The 
separated cells are then returned to the patient by intravenous 
transfusion. HemoSep efficacy has been demonstrated clinically 
using residual diluted bypass and circuit blood.20 The use of 
the technology was also associated with reduced postoperative 
bleeding and red blood cell transfusion, as well as a decrease in 
postcardiac bypass inflammatory response.21
Design considerations for the technology
The proposed system consists of two peristaltic pumps, driven 
from a single drive shaft with independent activation. The 
primary pump provides the suction, removing blood from the 
wound site to a settlement reservoir. The secondary pump can 
be activated using a simple switch mechanism and returns blood 
to the casualty at a consistent flow rate of up to 500 mL/min via 
an infusion line. This arrangement permits transfusion of blood 
intermittently to the casualty without interrupting the critical 
suction of blood from the wound site. In this way, constant auto-
transfusion can be carried out, controlling two pumps from one 
drive shaft. This thereby reduces the complexity of the technique 
insofar as only one drive crank needs to be used. Early auto-
transfusion may ensure efficient patient stabilisation to increase 
likelihood of survivability from the field to a medical facility. 
To maximise the impact and efficiency of the field-deployable 
autotransfusion system, the innovation comprises two primary 
technologies:
Pump system
This is a field-deployable military autotransfusion system which 
is lightweight, compact and manually operable. The core system 
would comprise a suction nozzle and tubing to evacuate blood 
from the wound site to a collection bag using a manually powered 
pump, and also incorporates a HemoSep haemoconcentration 
processing bag (for use where appropriate), low level anticoagu-
lant-infused crystalloid fluid and a transfusion bag (Figure 1A):
 Ź The collection bag receives blood from the wound via the 
pump; fluid suctioned from a wound site is a turbulent 
blood-air mixture. All air and major contaminants must 
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Figure 2 Flow chart of the autotransfusion and cell concentration 
processes. Under ield and evacuation scenarios where haemorrhaged 
blood is immediately re-transfused (left) and at a military treatment 
facility where autotransfusion is non-urgent (right).
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be removed before re-transfusion; the collection bag must 
perform these tasks efficiently without causing significant 
haemolysis. Where air intrusion into the system is unavoid-
able, this will ultimately be resolved by a settlement or air 
settlement reservoir.
 Ź The HemoSep processing bagnot essential if autotransfu-
sion is urgent to ensure patient stabilisationcan be easily 
and rapidly incorporated into the kit.
 Ź The blood is finally deposited into a transfusion bag for 
subsequent re-transfusion.
 Ź For field-deployability, the kit can be flat-packed (Figure 1B).
 Motorised docking station
We aimed to develop a plug-and-play motor-driven docking 
station for the pump to allow autotransfusion and blood concen-
tration in the military treatment facility. This would allow 
continual autotransfusion and blood concentration to ensure 
patient stabilisation. The autotransfusion process underpinning 
the development of the proposed technology and the design 
concept are shown in Figure 1.
Pump configuration
The system was designed as a single axle, independent double 
roller head, peristaltic pump mechanism, with two suctioning 
tubes capable of both constantly evacuating blood from the 
wound site and intermittently propelling this blood between the 
blood reservoir and the processing bag during use. The larger 
upper suction pump generates a vacuum to rapidly evacuate 
blood from the wound site via a manual hand-cranking peri-
staltic pump. A second pump positioned underneath (in its own 
chamber) will lie dormant until a mechanical latch is engaged 
that joins the axle from the first pump to the second. This will 
then rotate and cause the second pump to transport collected 
blood to the processing bag. The two pumps are connected to 
a common drive shaft, but operate independently using a latch 
system to activate the low flow system when required and to 
ensure that there is no interruption to blood evacuation during 
cell processing. This design was based on a conventional peri-
staltic roller mechanism, but in this case it has two roller heads, 
one capable of high flow (approximately 3 L/min) which is repre-
sentative of a large bleed and one with a low flow configuration 
(approximately 0.5 L/min) to transfer concentrated blood from a 
collection reservoir to the processing bag or patient.
The high flow evacuation pump can be operated constantly 
and the activation of the low flow pump head does not interfere 
with its function. The drive shaft can be hand cranked using a 
handle on the upper aspect of the pump, with gearing enabling 
easy crank operation. The pump system must be capable of 
constantly extracting blood from the wound site while moving 
the blood into the collection bag or Hemosep bag and returning 
blood to the patient only when desired. The pump cylinder was 
designed as three separate interlocking sections; the first section 
contained a multiplier gearbox to increase output speed; the 
second (upper suction pump) section housed the high flow roller 
mechanism while the third (lower pump) contained the low flow 
rollers and latch mechanism allowing its activation/deactiva-
tion. The technology has in-built versatility. Under first contact 
conditions, the device may solely provide critical autotransfu-
sion at point of injury and during transportation to immediately 
re-transfuse haemorrhaged blood. In the field hospital after casu-
alty evacuation, where autotransfusion is non-urgent, this can 
be converted to a cell concentration device to return cell species 
(Figure 2).
Tubing and pump speciications
Tubing and pump dimensions were based on initial concept ideas 
and design specification to create an ergonomic and portable 
pump. Pure platinum-cured silicone tubing was used for the 
upper pump (Watson-Marlow, Cornwall, UK) and lower pump 
(Cole Parmer, Hanwell, UK).
Pump system
Initial pump schematics were designed using Parametric Tech-
nology Corporation (PTC) Creo (PTC, Needham, Massachusetts, 
USA). The hardware, although complex, was designed for addi-
tive manufacturing techniques to ultimately enable the construc-
tion of lightweight components in a combination of aluminium 
and carbon fibre with a view to minimising the overall weight 
of the technology. For the pump prototype, all computer aided 
design (CAD) parts were three-dimensionally (3D) printed in 
aluminium (3D Alchemy, Sabre Software Development, Shrop-
shire, UK), excluding gears (HPC gears, Derbyshire, UK) and 
shafts and rollers (upper suction pump rollers (diameter 30 mm 
and 30 mm height), lower pump rollers (diameter 30 mm and 
15 mm height)) which were manufactured in-house in stainless 
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Figure 3 A computer aided design schematic of the pump mechanism. The spring-loaded lower compartment is manually twisted and locked in 
place to activate and deactivate when necessary.
Figure 4 Plug-and-play motor-driven docking station for the manual 
pump to allow autotransfusion and blood concentration in a military 
treatment facility.
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steel. Roller supports were also 3D printed in stainless steel 
(3D Alchemy, Sabre Software Development, Shropshire, UK) 
(Figure 3). For urgent field use, the technology was designed 
with a removable handle and adapted for compatibility with an 
electronic screwdriver. This would give the user the opportunity 
to operate the pump at a high revolutions per minute (RPM) 
without any physical exertion, and this was included to enable 
continual use during the evacuation and transport phase of 
medical intervention. As part of the design process, modelling 
suggested that a pump with a 1:1 gear ratio would be incapable 
of achieving targeted flow rates. However, a 1:2 gearbox would 
attain flow rates of 3.6 L/min and 0.57 L/min for the upper and 
lower pumps, respectively, and this gearbox was selected.
Motorised docking station development
The plug-and-play motor-driven docking station for the pump 
was developed for use at a medical treatment facility. A direct 
current (DC) geared motor (24 V DC, 24 Nm, 125 RPM, Mellor 
Electric, RS Components, UK) was coupled (Ruland Aluminium 
Flexible Beam Coupling, RS Components, UK) with the pump 
and powered with a DC power supply (Digimess Concept Series, 
Digimess Instruments, Derby, UK) (Figure 4).
Aims
The overall objective of our research programme is to develop 
a technology fit for routine application by non-specialists in 
an operational setting, where cells harvested by this device 
are rapidly and directly transfused back into the casualty, and 
offers critical primary autotransfusion on the battlefield for 
haemorrhaging soldiers or in other austere settings. Crucially, 
the proposed technology represents a single, versatile treatment 
modality that accommodates all stages of medical intervention, 
from first contact, through casualty evacuation and transport, 
and ultimately for use in the military field hospital. The key 
elements in informing the design process for this new technology 
were; lightweight, ensuring ease of deployment in the battlefield; 
independence from mains power, enhancing the ability to deploy 
in the most challenging and austere settings; and a high  flow 
capability, to enable blood salvage in the most severely injured 
casualty situations. The aim of this paper is to describe the key 
areas of activity involved in the design, development and feasi-
bility testing of the technology (Box). 
METHODOLOGY
Flow rate testing of the upper and lower pumps
The high flow pumping using the larger upper pump and low 
flow pumping capability of the smaller lower pump were tested 
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Figure 5 The low rates for the upper and lower suction pumps over 
a range of values. The upper suction pump values were calculated with 
and without the presence of air.
The three main aims of the research that encompass the design, 
development and feasibility testing of the portable blood salvage 
and auto-transfusion technology are:
 Ź To design, develop and bench test an auto-transfusion system 
that would facilitate rapid re-transfusion of blood to the 
casualty without the HemoSep® cell concentration cycle. 
This would permit rapid transfusion of whole blood to the 
casualty, reducing the processing time considerably.
 Ź To develop a powered drive system that would permit the 
function of the auto-transfusion system over prolonged 
periods by a single user. This would reduce the number of 
personnel required to perform auto-transfusion and sustain 
the process period.
 Ź To develop and bench test a ‘base station’ unit in order that 
the core system would be useable in the hospital setting as 
a HemoSep®/auto-transfusion system without the need for 
additional components. This system would have the effect 
of maximising the versatility of the system and broaden 
the availability of auto-transfusion throughout the patient 
journey.
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using the motorised docking station (in order to control RPM 
input). The pump was tested using fresh bovine blood collected 
from a local abattoir (Sandyford Abattoir, Paisley, UK) in a 
sealed container and treated with 10 000 IUs of heparin sodium 
from porcine mucosa (Sigma Aldrich, Dorset, UK) in 50 mL of 
0.9% sodium chloride solution. Flow rates were set between 
30 RPM and 75 RPM in accordance with realistic operational 
capabilities, and this was achieved by altering the voltage output 
of the power supply. For the upper and lower pumps, the inlet 
tubing was placed in a beaker containing 5 L and 2 L of blood, 
respectively, and the outlet tubing was placed in an empty 
beaker to measure volume of transferred blood. The flow rate 
was measured by calculating the time taken to transfer the blood 
through the pumplitres per minute was then subsequently 
calculated. Flow rate values were recorded at RPM values 
between 30 and 75 (Figure 5).
Upper suction pump flow rate
In real battlefield conditions, it would be anticipated that a 
mixture of blood and air would be suctioned during pump use, 
and as such, the flow rates under these conditions were also 
assessed. This was achieved by intermittently submerging the 
suction wand in the blood approximately every 2 s to collect 
both blood and air.
Lower pump flow rate
During pump deployment, blood is transferred from the collec-
tion bag to either the HemoSep processing or the transfu-
sion bagas such, no air enters this pump. The flow rate was 
measured by calculating the time taken to transfer 2 L of blood 
only through the pump and L/min subsequently calculated.
RESULTS
Upper suction pump flow rate
Using blood and an input of 60 RPM, the evacuation and suction 
of 5 L of blood took 112 s, and so 1 L of blood took 22.5 s. 
Therefore, the upper suction pump for this input had a flow rate 
of 2.67 L/min when using blood. Using a blood/air mixture the 
evacuation and suction of 5 L of blood took 240 s, and so 1 L of 
blood took 48 s. Therefore, the upper suction pump had a flow 
rate of 1.25 L/min when using a blood/air mixture.
Lower pump flow rate
Using blood the evacuation and suction of 2 L of blood took 
280 s, and so 1 L of blood took 140 s. Therefore, the upper 
suction pump had a flow rate of 0.43 L/min when using blood.
The output flow rates obtained during test were slightly lower 
than the theoretical values calculated. This could be due to a 
number of reasons. First, timing started from when the pump 
was initially activated and there is a delay before blood enters the 
pumpthis would account for a slight reduction in the output 
flow rate. Also, residual blood may remain in the tubing at the 
end of the test. Another possible reason for the lower output 
flow rates is that the roller inside the pump may not have fully 
occluded the tubethis could reduce pressure inside the pump 
and cause air to reside within the tubing. This would reduce 
the volume of blood inside the pump and as a result reduce the 
output flow rate.
DISCUSSION
The project primary objective was to develop a military version 
of the HemoSep device that is portable and can function inde-
pendently of mains power (Figure 6). On reviewing the landscape 
of military recovery, this objective was considerably broadened 
to cover the entire journey and circumstances of the military 
casualty. The project produced a device that was versatile, having 
manual, portable power-driven and mains-driven derivative 
devices with a low haemolysis profile. This technology offers the 
potential to treat the casualty from the point of injury, through 
to the postsurgical period in their treatment pathway using one 
core technology. Injured military personnel require aggressive 
and urgent haemostatic resuscitation to increase survivability 
through the entire journey from the battlefield to the mili-
tary hospital. Crucially, the proposed technology represents a 
single, versatile treatment modality that accommodates all stages 
of medical intervention (Figure 7). Since early intervention is 
crucial for haemorrhaging patients, our solution is a portable, 
efficient and rapid autotransfusion blood salvage device that 
recycles spilled blood at the point of injuryconcentrating the 
residual blood and returning all cell species including platelets 
and red blood cells back to the patient.
The environment in which this technology will be deployed 
is a challenging one. In particular, the presence of complex 
contaminants in the forward military surgical setting is of 
concern. Where these circumstances are recognised, the cell 
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Figure 6 Left, the completed, ield-deployable prototype in its closed bag and right, open with pump outside to display its contents.
Figure 7 The technology was designed to treat—through autotransfusion and cell concentration—the casualty throughout the entire journey from 
the point of injury, during the evacuation and transfer to hospital stage and ultimately at arrival at a military treatment hospital.
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concentration element of the device should be deployed, 
supported by the inclusion of proprietary transfusion filters in 
the return line. The inclusion of the blood concentration tech-
nology will extend the collection to delivery time for processed 
blood by around 10 min. In effect, the incorporation of the cell 
concentration element of the technology results in a delay in 
the transfusion process, associated with the processing of the 
first unit of blood; thereafter the system will operate essentially 
as an autotransfusion system. The transfusion of processed, 
concentrated cells also permits the administration of foreign 
expanders in proportion to the volume of plasma extracted 
while maintaining patient packed cell volume. However, under 
less challenging, and perhaps more common conditions, the 
system may be operated with the cell concentration system as a 
standard autotransfusion system. We would recommend the use 
of a return line filter in all circumstances.
This was entirely a laboratory-based study. Although based on 
the development of a blood salvage and autotransfusion tech-
nology that has been delivered to the global clinical community 
in partnership with our commercial partners Brightwake, we 
recognise that further work is required to determine its field 
deployability. Another limitation that needs to be addressed in 
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relation to the development work is to assess the effectiveness 
of the technology under near-clinical conditions, in particular 
to test its effectiveness in a situation mimetic of major battle-
field haemorrhage. It is conceivable that, under these condi-
tions, additional blood isolation technologies will be required 
to enhance the effectiveness of the device. These issues will be 
addressed prior to field deployment trials that will form part 
of the regulatory approval process for the device. We recognise 
that there may be a need to increase the blood handling capa-
bilities of the technology to cover the broad spectrum of lesions 
that the device may encounter in the field, but this will become 
apparent through the next stage of the device development 
process. However, it is clear that this technology as it stands has 
the capability to reduce the donor transfusion needs of injured 
personnel.
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